✨
Yapay Zeka Hızlı Bakış & Çıkarımlar
AI Insight⚡ TL;DR(1 Cümlede Hızlı Çıkarım)
This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life.
📊
Temel Bulgular & Veri:Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life.
💡
Sonuç & Katkı:This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:biyolojik · keilit · tildrakizumab
Abstract
Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
Anahtar kelimeler
🔖
Bu Makaleye Atıf Yap
COWAN, T., ALRUB, N. A., WİLSON, A., MAKHİJA, M., MURRELL, D. (2023). Eksfolyatif keilit tedavisinde tildrakizumab. Mucosa, Cilt: 6 - Sayı: 1, 19–21. https://ajindex.com/articles/879358